Valneva: Chikungunya Fever trials

The registry lists 11 Chikungunya Fever studies with Valneva as lead sponsor. 2 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 1Phase 3 5No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• VLA1553-403 Pregnancy Surveillance StudyEnrolling by invitationNCT07414524
• Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilEnrolling by invitationNCT07347002
• A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsCompletedNCT06106581Phase 2Results posted
• Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)Active, not recruitingNCT04838444Phase 3Results posted
• Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy AdultsCompletedNCT04786444Phase 3Results posted
• Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in AdultsCompletedNCT04546724Phase 3Results posted
• Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruitingNCT07254702
• Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruitingNCT07163845
• A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy ChildrenWithdrawnNCT07133178Phase 3
• A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)WithdrawnNCT06028841Phase 3
• Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy VolunteersCompletedNCT03382964Phase 1